RECEIVED CENTRAL FAX CENTER

ND.369 P001

JAN 0 9 2006

PTO/\$8/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/729,499 TRANSMITTAL Filing Date December 5, 2003 First Named Inventor FORM Elfatih Elzein Art Unit 1624 Examiner Name Bernhardt, Emily B. (to be used for all correspondence after initial filing) Attorney Docket Number 02 - 17528 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC X Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Provisional Application Proprietary Information Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Endosure(s) (please Identify Terminal Disdaimer Extension of Time Request Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name CV Therapeutics, Inc. Signature Printed name **Elin Hartrum** Date Reg. No. 43,663 January 9, 2006 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Samise with sufficient peetage as first class mail in a survivore addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (571) 273-8300 Signature Date Susan Ahearn 01/09/2006 Typed or printed name

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandría, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandría, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.

JAN 0 9 2006

Atty Dkt No. 02-0175

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

10:49

Elzein et al.

Confirmation No.: 8126

Serial No.: 10/729,499

Group Art Unit: 1624

Filing Date: December 5, 2003

Examiner: Bernhardt, Emily B.

Title: Substituted Heterocyclic Compounds

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA, 22313-1450

AMENDMENT UNDER 37 CFR § 1.111

In response to the Office action of October 12, 2005, please amend the above-identified application as follows.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of the claims that begins on page 5 of this paper.

Remarks begin on page 10 of this paper.